<!DOCTYPE html>
<html lang="en"><head>
<script src="index_files/libs/clipboard/clipboard.min.js"></script>
<script src="index_files/libs/quarto-html/tabby.min.js"></script>
<script src="index_files/libs/quarto-html/popper.min.js"></script>
<script src="index_files/libs/quarto-html/tippy.umd.min.js"></script>
<link href="index_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="index_files/libs/quarto-html/light-border.css" rel="stylesheet">
<link href="index_files/libs/quarto-html/quarto-html.min.css" rel="stylesheet" data-mode="light">
<link href="index_files/libs/quarto-html/quarto-syntax-highlighting-dark.css" rel="stylesheet" id="quarto-text-highlighting-styles"><meta charset="utf-8">
  <meta name="generator" content="quarto-1.3.450">

  <meta name="author" content="Dongyoun Kim">
  <title>Moderate statin+Ezetimibe VS High Statin in ASCVD patients</title>
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
  <link rel="stylesheet" href="index_files/libs/revealjs/dist/reset.css">
  <link rel="stylesheet" href="index_files/libs/revealjs/dist/reveal.css">
  <style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    ul.task-list{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      width: 0.8em;
      margin: 0 0.8em 0.2em -1em; /* quarto-specific, see https://github.com/quarto-dev/quarto-cli/issues/4556 */ 
      vertical-align: middle;
    }
  </style>
  <link rel="stylesheet" href="index_files/libs/revealjs/dist/theme/quarto.css">
  <link href="index_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.css" rel="stylesheet">
  <link href="index_files/libs/revealjs/plugin/reveal-menu/menu.css" rel="stylesheet">
  <link href="index_files/libs/revealjs/plugin/reveal-menu/quarto-menu.css" rel="stylesheet">
  <link href="index_files/libs/revealjs/plugin/quarto-support/footer.css" rel="stylesheet">
  <style type="text/css">

  .callout {
    margin-top: 1em;
    margin-bottom: 1em;  
    border-radius: .25rem;
  }

  .callout.callout-style-simple { 
    padding: 0em 0.5em;
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
    display: flex;
  }

  .callout.callout-style-default {
    border-left: solid #acacac .3rem;
    border-right: solid 1px silver;
    border-top: solid 1px silver;
    border-bottom: solid 1px silver;
  }

  .callout .callout-body-container {
    flex-grow: 1;
  }

  .callout.callout-style-simple .callout-body {
    font-size: 1rem;
    font-weight: 400;
  }

  .callout.callout-style-default .callout-body {
    font-size: 0.9rem;
    font-weight: 400;
  }

  .callout.callout-titled.callout-style-simple .callout-body {
    margin-top: 0.2em;
  }

  .callout:not(.callout-titled) .callout-body {
      display: flex;
  }

  .callout:not(.no-icon).callout-titled.callout-style-simple .callout-content {
    padding-left: 1.6em;
  }

  .callout.callout-titled .callout-header {
    padding-top: 0.2em;
    margin-bottom: -0.2em;
  }

  .callout.callout-titled .callout-title  p {
    margin-top: 0.5em;
    margin-bottom: 0.5em;
  }
    
  .callout.callout-titled.callout-style-simple .callout-content  p {
    margin-top: 0;
  }

  .callout.callout-titled.callout-style-default .callout-content  p {
    margin-top: 0.7em;
  }

  .callout.callout-style-simple div.callout-title {
    border-bottom: none;
    font-size: .9rem;
    font-weight: 600;
    opacity: 75%;
  }

  .callout.callout-style-default  div.callout-title {
    border-bottom: none;
    font-weight: 600;
    opacity: 85%;
    font-size: 0.9rem;
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-default div.callout-content {
    padding-left: 0.5em;
    padding-right: 0.5em;
  }

  .callout.callout-style-simple .callout-icon::before {
    height: 1rem;
    width: 1rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 1rem 1rem;
  }

  .callout.callout-style-default .callout-icon::before {
    height: 0.9rem;
    width: 0.9rem;
    display: inline-block;
    content: "";
    background-repeat: no-repeat;
    background-size: 0.9rem 0.9rem;
  }

  .callout-title {
    display: flex
  }
    
  .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  .callout.no-icon::before {
    display: none !important;
  }

  .callout.callout-titled .callout-body > .callout-content > :last-child {
    margin-bottom: 0.5rem;
  }

  .callout.callout-titled .callout-icon::before {
    margin-top: .5rem;
    padding-right: .5rem;
  }

  .callout:not(.callout-titled) .callout-icon::before {
    margin-top: 1rem;
    padding-right: .5rem;
  }

  /* Callout Types */

  div.callout-note {
    border-left-color: #4582ec !important;
  }

  div.callout-note .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-note.callout-style-default .callout-title {
    background-color: #dae6fb
  }

  div.callout-important {
    border-left-color: #d9534f !important;
  }

  div.callout-important .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-important.callout-style-default .callout-title {
    background-color: #f7dddc
  }

  div.callout-warning {
    border-left-color: #f0ad4e !important;
  }

  div.callout-warning .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-warning.callout-style-default .callout-title {
    background-color: #fcefdc
  }

  div.callout-tip {
    border-left-color: #02b875 !important;
  }

  div.callout-tip .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-tip.callout-style-default .callout-title {
    background-color: #ccf1e3
  }

  div.callout-caution {
    border-left-color: #fd7e14 !important;
  }

  div.callout-caution .callout-icon::before {
    background-image: url('data:image/png;base64,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');
  }

  div.callout-caution.callout-style-default .callout-title {
    background-color: #ffe5d0
  }

  </style>
  <style type="text/css">
    .reveal div.sourceCode {
      margin: 0;
      overflow: auto;
    }
    .reveal div.hanging-indent {
      margin-left: 1em;
      text-indent: -1em;
    }
    .reveal .slide:not(.center) {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide.scrollable {
      overflow-y: auto;
    }
    .reveal .footnotes {
      height: 100%;
      overflow-y: auto;
    }
    .reveal .slide .absolute {
      position: absolute;
      display: block;
    }
    .reveal .footnotes ol {
      counter-reset: ol;
      list-style-type: none; 
      margin-left: 0;
    }
    .reveal .footnotes ol li:before {
      counter-increment: ol;
      content: counter(ol) ". "; 
    }
    .reveal .footnotes ol li > p:first-child {
      display: inline-block;
    }
    .reveal .slide ul,
    .reveal .slide ol {
      margin-bottom: 0.5em;
    }
    .reveal .slide ul li,
    .reveal .slide ol li {
      margin-top: 0.4em;
      margin-bottom: 0.2em;
    }
    .reveal .slide ul[role="tablist"] li {
      margin-bottom: 0;
    }
    .reveal .slide ul li > *:first-child,
    .reveal .slide ol li > *:first-child {
      margin-block-start: 0;
    }
    .reveal .slide ul li > *:last-child,
    .reveal .slide ol li > *:last-child {
      margin-block-end: 0;
    }
    .reveal .slide .columns:nth-child(3) {
      margin-block-start: 0.8em;
    }
    .reveal blockquote {
      box-shadow: none;
    }
    .reveal .tippy-content>* {
      margin-top: 0.2em;
      margin-bottom: 0.7em;
    }
    .reveal .tippy-content>*:last-child {
      margin-bottom: 0.2em;
    }
    .reveal .slide > img.stretch.quarto-figure-center,
    .reveal .slide > img.r-stretch.quarto-figure-center {
      display: block;
      margin-left: auto;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-left,
    .reveal .slide > img.r-stretch.quarto-figure-left  {
      display: block;
      margin-left: 0;
      margin-right: auto; 
    }
    .reveal .slide > img.stretch.quarto-figure-right,
    .reveal .slide > img.r-stretch.quarto-figure-right  {
      display: block;
      margin-left: auto;
      margin-right: 0; 
    }
  </style>
</head>
<body class="quarto-dark">
  <div class="reveal">
    <div class="slides">

<section id="title-slide" class="quarto-title-block center">
  <h1 class="title">Moderate statin+Ezetimibe VS High Statin in ASCVD patients</h1>
  <p class="subtitle">Long-term efficacy and safety of moderate-intensity statin with ezetimibe VS high-intensity monotherapy</p>

<div class="quarto-title-authors">
<div class="quarto-title-author">
<div class="quarto-title-author-name">
Dongyoun Kim 
</div>
</div>
</div>

</section>
<section>
<section id="definition" class="title-slide slide level1 center">
<h1>Definition</h1>

</section>
<section id="이상지질혈증" class="slide level2 smaller">
<h2>이상지질혈증</h2>
<ul>
<li><strong>Dyslipidemia</strong> : 이상지질혈증; 혈액 내 지질 성분 중 콜레스테롤과 중성지방 등이 증가하고 좋은 콜레스테롤인 HDL-콜레스테롤이 감소한 상태를 의미한다.</li>
<li>지질단백은 각 지질 성분의 비율에 따라 VLDL, LDL, HDL 등으로 구분된다.</li>
<li><strong>LDL</strong> (Low-density lipoprotein) <strong>cholesterol</strong> : 저밀도 지단백 콜레스테롤; ’나쁜 콜레스테롤’로 알려져 있다. 이는 LDL이 혈관벽에 과도한 콜레스테롤 침착을 유발해서 <strong>죽상동맥경화증,</strong> 위험을 높이기 때문이다. 때문에 <strong>심혈관질환자들에게서 발병하는 심근경색이나 뇌졸중 재발, 심인성 사망을 막기 위해 LDL 콜레스테롤 수치를 낮게 유지</strong>하는 것이 무엇보다 중요하다.</li>
</ul>
</section>
<section id="ascvd" class="slide level2">
<h2>ASCVD</h2>
<ul>
<li><p><strong>A</strong>thero<strong>S</strong>clerotic <strong>C</strong>ardio<strong>V</strong>ascular <strong>D</strong>isease; 죽상동맥경화증성 혈관질환군</p></li>
<li><p>지질 수치를 교정하는 주 목적은 <strong>ASCVD 예방</strong>!</p></li>
<li><p>2013년 AHA/ACC 가이드라인에서는 ASCVD를 아래와 같이 정의하였다.</p>
<ul>
<li>급성 관상동맥 증후군, 심근경색, 협심증, 관상동맥 또는 동맥 혈관재관류술, 뇌경색, 일과성허혈, 말초혈관질환,대동맥류를 포함</li>
</ul></li>
</ul>
</section>
<section id="이상지질혈증의-치료" class="slide level2 smaller">
<h2>이상지질혈증의 치료</h2>
<ul>
<li><p><strong>Statin</strong> (HMG-CoA 환원 효소 저해제)</p>
<ul>
<li>간(몸 속 콜레스테롤 공장)의 콜레스테롤 합성을 저하시켜 혈관 내 LDL 콜레스테롤을 줄여준다.</li>
</ul></li>
<li><p><strong>Ezetimibe</strong> : 음식으로 섭취한 콜레스테롤이 소장에서 체내로 다시 흡수되는 것을 막아준다.</p>
<ul>
<li><p>음식물이나 담즙산의 형태로 분비되는 내인성 콜레스테롤은 소장에 존재하는 콜레스테롤 운반 단백질 통로(Niemann Pick Cell 1 Like 1, NPC1L1)를 통해 간으로 이동, 저장된다.</p></li>
<li><p>에제티미브는 이 과정을 저해하여 콜레스테롤의 간 저장량을 감소시키고, 체외로 빠져나가는 것을 돕는다.</p></li>
</ul></li>
</ul>
</section></section>
<section>
<section id="background" class="title-slide slide level1 center">
<h1>Background</h1>

</section>
<section id="스타틴-증량-vs-병용-요법" class="slide level2 smaller">
<h2>스타틴 증량 VS 병용 요법</h2>
<ul>
<li>여러 가이드라인에서 ASCVD 고위험 환자에게 고강도 스타틴을 강력히 권고해왔으나, 스타틴은 용량과 비례하여 근육통, 신규 당뇨병 등의 부작용 위험을 높일 우려가 있다.</li>
<li>일반적으로 고용량으로 단일 약물을 사용하는 대신 여러 약물을 조합하면 효능(efficaty)는 높이고 위험은 줄일 수 있다.</li>
<li>이와 같은 맥락에서, 스타틴만으로 목표 LDL-C 도달이 어려울 경우 고강도 스타틴 단독 대신 중등도 강도 스타틴과 에제티미브(Ezetimibe) 병합 요법이 대안으로 제시되었다.</li>
</ul>
</section>
<section id="기존-연구의-한계" class="slide level2 smaller">
<h2>기존 연구의 한계</h2>
<ul>
<li><p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1410489">IMPROVE-IT</a> trial (2015) : 스타틴에 비스타틴 치료인 에제티미브를 추가하는 병용요법의 가치를 최초로 입증</p>
<ul>
<li><p>simvastatin 40 mg + ezetimibe 10 mg 투여 군과 simvastatin 40 mg 단독투여 군을 비교</p></li>
<li><p>주요 심혈관 사건 : 병용요법 대상자 중 32.7%, 단독투여 대상자에서는 34.7%로, <strong>병용요법 사용 시 절대적 위험 감소가 2.0%</strong>로 유의미하게 크게 나타났다.</p></li>
<li><p>한계</p>
<ul>
<li><p><strong>같은 용량의 simavastatin에 추가된 ezetimibe의 부가적인 효과만을 설확인</strong>할 수 있도록 (add-on ezetimibe treatment to the same dose statin) 임상시험을 설계한 탓에 ezetimibe의 고유한 효과를 검증할 수 없었다.</p></li>
<li><p>LDL 수치를 적정 수치까지 낮출 수 없을 경우 고용량 스타틴으로 넘어가야 할지, 저용량 스타틴에 비스타틴계인 에제티미브를 더한 복합 요법을 선택해야 할지에 대한 답은 주지 못했다.</p></li>
</ul></li>
</ul></li>
<li><p>즉, AVCSD 환자에 대해 <u>두 치료 전략(용량 줄인 스타틴+에제티미브 VS 기존의 고용량 스타틴 단독)의 임상 결과를 비교한 <strong>1년 이상의 장기적인</strong> 추적 RCT 연구는 없었다</u>.</p>
<ul>
<li>이 때문에 기존 가이드라인에서는 최대 가용 스타틴에도 LDL-C가 조절되지 않을 때에 도달하고 나서야 ezetimibe의 병용을 권고한다.</li>
</ul></li>
<li><p><strong>RACING</strong> <strong>trial</strong> 의의 : 3년 간의 효능과 안전성 (3-year clinical efficacy and safety)의 측면에서 <strong>moderate-intensity statin+ezetimibe 병용 요법이 high-intensity statins 대비 비열등한지 검정(noninferiority)</strong></p></li>
</ul>
</section></section>
<section>
<section id="method" class="title-slide slide level1 center">
<h1>Method</h1>
<div class="panel-tabset">
<ul id="tabset-1" class="panel-tabset-tabby"><li><a data-tabby-default="" href="#tabset-1-1">Study design</a></li><li><a href="#tabset-1-2">Population</a></li><li><a href="#tabset-1-3">Study Design</a></li><li><a href="#tabset-1-4">Study Procedures</a></li><li><a href="#tabset-1-5">Randomization</a></li></ul>
<div class="tab-content">
<div id="tabset-1-1">
<ul>
<li>investigator-initiated, multicentre, randomised, open-label, clinical, non-inferiority trial
<ul>
<li>Multi-center : 국내 26개 병원</li>
<li>Enrollment : 2017/2/14~2018/12/18</li>
<li>3년 동안 추적관찰함.
<ul>
<li>추적 관찰 기간 동안 내원 시점 : 2m, 6m, 이후 every yr</li>
<li>지질 수치 : 1yr, 2yr, 3yr</li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="tabset-1-2">
<ul>
<li><p>Inclusion Criteria</p>
<ul>
<li><p>19-80세</p></li>
<li><p>심혈관질환 (다음 중 적어도 하나) 진단: 이전 심근 경색, 급성 관상 동맥 증후군, 재관류시술, 허혈성 뇌졸중 및 말초동맥질환</p></li>
</ul></li>
<li><p>Exclusion Criteria</p>
<ul>
<li><p>활성 간질환 또는 지속적 간수치 (AST, ALT≥2UNL) 상승</p></li>
<li><p>약제 알레르기 또는 과민 반응</p></li>
<li><p>장기 이식 수혜자</p></li>
<li><p>스타틴 중단이 필요한 부작용 병력</p></li>
<li><p>임신/임신가능성/수유 중인 여성</p></li>
<li><p>3년 미만의 기대 여명</p></li>
<li><p>등록 후 1년 동안 추적이 불가능한 경우</p></li>
</ul></li>
</ul>
</div>
<div id="tabset-1-3">
<p><img data-src="RACING%20Supplement/RACING%20Study%20design.jpg"></p>
</div>
<div id="tabset-1-4">
<ol type="1">
<li><p><strong>moderate-intensity statin with ezetimibe combination therapy</strong> <u>(이하 <strong>Combination</strong>군</u>) : 병용요법</p>
<ul>
<li>rosuvastatin 10 mg with ezetimibe 10 mg once daily</li>
</ul></li>
<li><p><strong>high-intensity statin monotherapy</strong> (<u>이하 <strong>High</strong>군</u>) : <u>고강도 스타틴 단독요법</u></p>
<ul>
<li>high intensity statin : rosuvastatin 20 mg once daily</li>
</ul></li>
</ol>
</div>
<div id="tabset-1-5">
<ul>
<li>Combination, High 군에 <strong>1:1 무작위 배정</strong>하고,
<ul>
<li>기저 LDL-C 수치 (100mg/dL 기준), 당뇨 여부에 따라 <strong>층화 분석함.</strong></li>
</ul></li>
</ul>
</div>
</div>
</div>
</section>
<section id="criteria-of-revascularization-successful-pci" class="slide level2">
<h2>Study Endpoint</h2>
<div class="panel-tabset">
<ul id="tabset-2" class="panel-tabset-tabby"><li><a data-tabby-default="" href="#tabset-2-1">Primary Endpoint</a></li><li><a href="#tabset-2-2">Secondary Endpoint</a></li></ul>
<div class="tab-content">
<div id="tabset-2-1">
<ul>
<li>아래로 구성된, 3년 동안의 심뇌혈관질환 사망/발생률</li>
<li>구성요소 : <strong>cardiovascular death</strong> (심혈관질환에 의한 사망) + <strong>major cardiovascular events</strong> (주요 심혈관질환) + <strong>non-fatal stroke</strong> (비치명적 뇌졸중)</li>
</ul>
</div>
<div id="tabset-2-2">
<ul>
<li><p><strong>효능 (clinical efficacy)</strong></p>
<ul>
<li><p>1,2,3년째에 LDL-C 수치가 70mg/dL미만으로 잘 조절된 환자의 비율</p>
<ul>
<li>본 연구가 시작된 후 2019년 <a href="doi:10.1093/eurheartj/%20ehz455">ESC/EAS guideline</a>에서는 목표치로 55mg/dL를 권고함에 따라, 사후 분석 (post-hoc analysis)에서는 LDL-C 수치가 55mg/dL 미만인 환자 비율도 포함함.</li>
</ul></li>
<li><p>all cause death(모든 원인에 의한 사망) + major cardiovascular events (주요 심혈관질환) + non-fatal stroke (비치명적 뇌졸중)</p></li>
<li><p>LDL-C 수치 감소 백분율 (baseline - follow up)</p></li>
<li><p>primary endpoint의 개별 구성 요소</p></li>
</ul></li>
<li><p><strong>안전성 (safety)</strong></p>
<ul>
<li><p>약제 불내성에 의한 연구 약물의 중단 또는 용량 감량</p></li>
<li><p>부작용 : 새로 발병한 당뇨병, 근육/간/담낭 관련 부작용 또는 암 진단</p></li>
</ul></li>
</ul>
</div>
</div>
</div>
</section>
<section id="statistical-analysis" class="slide level2">
<h2>Statistical Analysis</h2>
<div class="panel-tabset">
<ul id="tabset-3" class="panel-tabset-tabby"><li><a data-tabby-default="" href="#tabset-3-1">Objectives</a></li><li><a href="#tabset-3-2">Primary Objective</a></li><li><a href="#tabset-3-3">Secondary Objective</a></li><li><a href="#tabset-3-4">Statistical analysis</a></li></ul>
<div class="tab-content">
<div id="tabset-3-1">
<ul>
<li>Primary Objective 가 유의하게 확인되는 경우 Secondary Objective 검증
<ul>
<li><strong>주요 목표</strong> (primary objective)
<ul>
<li>primary endpoint의 발생</li>
<li>Combination 군의 High 군 대비 <strong>비열등성</strong> 검정</li>
</ul></li>
<li><strong>이차적 목표</strong> (secondary objective)
<ul>
<li>efficacy endpoint 인 <strong>목표 LDL-C(&lt;70mg/dL)</strong> 의 달성</li>
<li>Combination 군의 High 군 대비 <strong>우월성</strong> 검정</li>
</ul></li>
</ul></li>
</ul>
</div>
<div id="tabset-3-2">
<ul>
<li>가정 : 3년째 primary outcome의 발생률이 Combination 그룹에서는 13%, High 그룹에서는 14%라고 가정함. (추정 근거 : IMPROVE-IT TRIAL)</li>
<li>intention-to-treat population with <strong>a non-inferiority margin of 2.0%</strong>
<ul>
<li>primary endpoint 발생률 차이에 대한 신뢰구간 상한 &lt; 2.0%일 경우 비열등</li>
</ul></li>
<li>Statistical Power (검정력) : 80%</li>
<li>단측검정, type 1 error rate 5.0%</li>
<li>탈락률 15% 예상</li>
<li><strong>Sample size : 3780명 (각 그룹당 1890명)</strong> 필요</li>
</ul>
</div>
<div id="tabset-3-3">
<ul>
<li>가정 : 3년째 목표 LDL-C의 달성률이 Combination 그룹에서는 70%, High 그룹에서는 50%라고 가정함. (추정 근거 : IMPROVE-IT TRIAL)</li>
<li>Statistical Power (검정력) : 80%</li>
<li>양측검정, type 1 error rate 5.0%</li>
<li>탈락률 15% 예상</li>
<li><strong>Sample size : 220명</strong> 필요 -&gt; primary objective 검증에 필요한 수만으로도 충분!</li>
</ul>
</div>
<div id="tabset-3-4">
<ul>
<li><p>Primary endpoint</p>
<ul>
<li><strong>Kaplan-Meier survival analysis</strong> with log rank test: 3년 primary outcome의 누적 발생률 추정
<ul>
<li>time : 등록 시점~event of interest가 발생한 시점</li>
</ul></li>
<li><strong>Cox proportional-hazards regression</strong>
<ul>
<li>95% 신뢰구간을 가진 hazard ration 추정</li>
</ul></li>
</ul></li>
<li><p>Secondary endpoint - efficacy</p>
<ul>
<li><strong>log rank test</strong></li>
</ul></li>
<li><p><strong>Intention-to-treat</strong> 분석 시행</p></li>
<li><p>Multiplicity 교정은 x</p></li>
<li><p>결측치는 대체하지 않고 제거</p></li>
</ul>
</div>
</div>
</div>
</section></section>
<section>
<section id="results" class="title-slide slide level1 center">
<h1>Results</h1>

</section>
<section id="baseline-characteristics" class="slide level2">
<h2>Baseline characteristics</h2>
<div class="panel-tabset">
<ul id="tabset-4" class="panel-tabset-tabby"><li><a data-tabby-default="" href="#tabset-4-1">Table 1.</a></li><li><a href="#tabset-4-2">Summary</a></li></ul>
<div class="tab-content">
<div id="tabset-4-1">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="RACING%20Supplement/RACING%20Table%201.png"></p>
</figure>
</div>
</div>
<div id="tabset-4-2">
<ul>
<li><strong>모집 대상</strong>: 3780명 (2017/2/14~2018/12/18)</li>
<li><strong>분석 대상</strong>: <strong>Combination 그룹 1894명, High 그룹 1886명</strong>
<ul>
<li>이 중 3622명(95.8%)에 대해서 3년 추적 완료</li>
</ul></li>
<li><u><strong>두 그룹 사이 baseline characteristics 에는 통계적으로 유의미한 차이가 없었다.</strong></u></li>
<li>평균 나이 64세, 남성이 75%</li>
<li>무작위 배정 전 환자들이 복용 중이었던 statin : high-intensity statin 38%, moderate-intensity statin 36%, 13% moderate-intensity statin + ezetimibe</li>
<li>처방받은 용량대로 복용 환자 비율</li>
</ul>
<table>
<thead>
<tr class="header">
<th></th>
<th>연구 1년째</th>
<th>연구 2년째</th>
<th>연구 3년째</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Combination 그룹</td>
<td>95%</td>
<td>94%</td>
<td>93%</td>
</tr>
<tr class="even">
<td>High 그룹</td>
<td>94%</td>
<td>91%</td>
<td>90%</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</section>
<section id="outcomes" class="slide level2">
<h2>Outcomes</h2>
<div class="panel-tabset">
<ul id="tabset-5" class="panel-tabset-tabby"><li><a data-tabby-default="" href="#tabset-5-1">Figure 2</a></li><li><a href="#tabset-5-2">Table 2</a></li><li><a href="#tabset-5-3">Primary/Secondary Outcome</a></li><li><a href="#tabset-5-4">Subgroup Analysis, Per-Protocol Population</a></li></ul>
<div class="tab-content">
<div id="tabset-5-1">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="RACING%20Supplement/RACING%20Figure%202.jpg"></p>
</figure>
</div>
</div>
<div id="tabset-5-2">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="RACING%20Supplement/RACING%20Table%202.png"></p>
</figure>
</div>
</div>
<div id="tabset-5-3">
<ul>
<li><strong>Primary outcome</strong> (투여 후 3년 시점에서의 심혈관계 사망, 뇌졸중, 주요 심혈관 사건 발생률) : <strong>Combination 그룹 9.1%, High 그룹 9.9%</strong>
<ul>
<li>두 군간 차이는 -0.78%로 나타나 통계적으로 의미있지 않다. (90% 신뢰구간 -2.39 ~ 0.83%)</li>
<li>Combination 그룹은 High 그룹 대비 비열등 (<strong>p-value &lt; 0.001</strong>) <br><br></li>
</ul></li>
<li><strong>Secondary outcome</strong></li>
</ul>
<ol type="1">
<li><u><strong>LDL-C 목표 수치 (&lt; 70mg/dL) 도달률</strong></u></li>
</ol>
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="RACING%20Supplement/RACING%20Table%203.png"></p>
</figure>
</div>
<ul>
<li><u><strong>목표도달율은모든 관찰시점에서 병용요법이 유의하게 우수</strong>한 것으로 확인되었다.</u> (all p value &lt; 0.0001)
<ul>
<li>고강도 스타틴 단독 요법군(High)
<ul>
<li>1년 : 55%, 2년 : 60%, <strong>3년 : 58%</strong></li>
</ul></li>
<li>병용요법군(Combination)
<ul>
<li>1년 : 73%, 2년 : 75%, <strong>3년 : 72%</strong>)</li>
</ul></li>
</ul></li>
<li>사후검정 : LDL-C &lt;55 mg/dL 도달율도 <u><strong>모든 관찰시점에서 병용요법이 유의하게 우수</strong></u>
<ul>
<li>고강도 스타틴 단독 요법군(High)
<ul>
<li>1년 : 25%, 2년 : 29%, 3년 : 25%</li>
</ul></li>
<li>병용요법군(Combination)
<ul>
<li>1년 : 42%, 2년 : 45%, 3년 : 42%</li>
</ul></li>
</ul></li>
</ul>
<ol start="2" type="1">
<li><p><u>중등도~고용량 <strong>스타틴 부작용이나 불내성으로</strong> 인한 <strong>약제 중단 또는 용량 감량</strong>한 환자 비율</u></p>
<p><img data-src="RACING%20Supplement/RACING%20Table%204.png"></p></li>
</ol>
<ul>
<li>고용량 스타틴 단독요법군(8.2%)과 비교하여 <strong>병용요법군 (4.8%)에서 더 적게 발생</strong> (p&lt;0.0001)</li>
</ul>
</div>
<div id="tabset-5-4">
<div class="quarto-figure quarto-figure-center">
<figure>
<p><img data-src="RACING%20Supplement/RACING%20Figure%203.png"></p>
</figure>
</div>
<ul>
<li>Subgroup, Per-Protocol 분석에서도 결과의 경향성은 유지 (Absolute difference는 산술적 수치상으로는 모두 더 낮은 결과. 다만, 통계적으로 유의한 차이를 보이지는 x)</li>
</ul>
</div>
</div>
</div>
</section></section>
<section>
<section id="conclusion" class="title-slide slide level1 center">
<h1>Conclusion</h1>
<ul>
<li>ASCVD 환자에서, 3년 심혈관계 사망, 뇌졸중, 또는 주요 심혈관 사건 발생률을 종합한 예후는 <strong>중등도 강도의 스타틴과 에제티미브(Ezetimibe) 병합 요법이</strong> 고강도 스타틴 단독요법 대비 <strong>비열등했다.</strong></li>
<li><strong>병합 요법</strong>에서 70mg/dL 이하의 <strong>LDL 콜레스테롤 농도에 도달한 환자의 비율이 높았으며,</strong> <strong>부작용</strong>으로 인한 약물 중단 또는 용량 감소가 <strong>적게 관찰되었다.</strong></li>
</ul>
</section>
<section id="discussion" class="slide level2">
<h2>Discussion</h2>
<div class="panel-tabset">
<ul id="tabset-6" class="panel-tabset-tabby"><li><a data-tabby-default="" href="#tabset-6-1">Discussion Points</a></li><li><a href="#tabset-6-2"></a><a href="http://m.mostonline.co.kr/news/articleView.html?idxno=97652"><strong>후속연구</strong></a></li></ul>
<div class="tab-content">
<div id="tabset-6-1">
<ol type="1">
<li><p>Superiority trial로 평가하기 위해서는 초기에 예상했던 것보다 더 많은 환자 수가 필요했다.</p></li>
<li><p>(기존에 사용하는 중등도 스타틴으로 LDL 을 충분히 낮출 수 없을 경우)</p>
<p>Q. statin을 고강도로 증량? 아니면 ezetimibe를 더한 복합 요법을 선택?</p>
<p>A. <u>스타틴 부작용 및 불내성 위험이 높은 환자</u>에서는 statin 증량 대신 <u>ezetimibe 병용요법을 우선 고려해볼 수 있다.</u></p>
<ul>
<li>스타틴 불내성 위험인자 : 고령, 여성, 비만, 당뇨, 갑상선저하증, 만성 간질환, 신부전 환자 등</li>
</ul></li>
<li><p>Moderate Intensity Statin + Ezetimibe 병용요법이 High Intensity 단독요법군에 비해 열등하지 않았던 이유</p>
<ul>
<li><p>Combination 요법이 LDL-C level을 유의미하게 낮추었기 때문</p>
<ul>
<li>LDL-C 감소 정도 = 주요 심혈관질환 위험의 가장 강력한 예측 인자 (지질강하제 종류와 무관)</li>
</ul></li>
<li><p>LDL-C를 낮추는 것 외에도, Ezetimibe가 아래 기능을 수행하기 때문</p>
<ul>
<li>죽상경화반 (plaque)의 안정화, 염증반응에 관여하는 유전자 조절, 혈관평활근 세포 증식 억제, 혈소판 응집 억제 등</li>
</ul></li>
</ul></li>
</ol>
<section id="의의" class="slide level2">
<h2>의의</h2>
<ul>
<li>세계 최초로 로수바스타틴+에제티미브 복합제의 Long-term outcome을 입증
<ul>
<li>한국지질·동맥경화학회의&nbsp;<a href="https://www.lipid.or.kr/reference/guideline.php?mode=view&amp;idx=1266">이상지질혈증&nbsp;진료지침&nbsp;제5판</a>에서도&nbsp;에제티미브(ezetimibe)의&nbsp;권고등급이&nbsp;Class&nbsp;Ⅱa에서&nbsp;Class&nbsp;ⅠB로&nbsp;상향됐으며,&nbsp;직접적으로&nbsp;RACING&nbsp;trial을&nbsp;인용한&nbsp;바&nbsp;있다.&nbsp;</li>
</ul></li>
<li>스타틴 이상반응은 대부분 투여 용량에 영향을 받으므로 용량을 줄일 수 있다는 점에서 유용
<ul>
<li>특히 동양인에서 스타틴 이상반응이 보다 많다고 알려져 있기에 RACING 연구가 시사하는 바가 크다.</li>
</ul></li>
</ul>
</section>
</div>
<div id="tabset-6-2">
<ul>
<li>당뇨병&nbsp;동반,&nbsp;노인,&nbsp;경피적관상동맥중재술(PCI)&nbsp;이후,&nbsp;초고위험군에&nbsp;대한&nbsp;RACING&nbsp;sub&nbsp;study</li>
<li>2023년 8월 JACC(Journal of the American College of Cardiology) : Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention</li>
</ul>
</div>
</div>
</div>
</section>
<section id="limitations" class="slide level2 smaller">
<h2>Limitations</h2>
<ol type="1">
<li><strong>open-label</strong>
<ul>
<li>의사와 환자 모두 투여되는 스타틴의 용량에 대해 인지하고 있었다.</li>
</ul></li>
<li>기대에 비해 <strong>낮은 사건발생률</strong>이 관찰되었다.
<ul>
<li>2.0%라는 고정된 non-inferiority margin이 hazard ratio에 대해 지나치게 관대한 신뢰구간을 허용했을 가능성</li>
</ul></li>
<li>Primary outcome 내의 개별 임상 결과를 비교하는 것은 <strong>사건 수가 적어</strong> 어려웠다.</li>
</ol>
<div class="footer footer-default">
<p>RACING TRIAL</p>
</div>
</section></section>
    </div>
  </div>

  <script>window.backupDefine = window.define; window.define = undefined;</script>
  <script src="index_files/libs/revealjs/dist/reveal.js"></script>
  <!-- reveal.js plugins -->
  <script src="index_files/libs/revealjs/plugin/quarto-line-highlight/line-highlight.js"></script>
  <script src="index_files/libs/revealjs/plugin/pdf-export/pdfexport.js"></script>
  <script src="index_files/libs/revealjs/plugin/reveal-menu/menu.js"></script>
  <script src="index_files/libs/revealjs/plugin/reveal-menu/quarto-menu.js"></script>
  <script src="index_files/libs/revealjs/plugin/quarto-support/support.js"></script>
  

  <script src="index_files/libs/revealjs/plugin/notes/notes.js"></script>
  <script src="index_files/libs/revealjs/plugin/search/search.js"></script>
  <script src="index_files/libs/revealjs/plugin/zoom/zoom.js"></script>
  <script src="index_files/libs/revealjs/plugin/math/math.js"></script>
  <script>window.define = window.backupDefine; window.backupDefine = undefined;</script>

  <script>

      // Full list of configuration options available at:
      // https://revealjs.com/config/
      Reveal.initialize({
'controlsAuto': true,
'previewLinksAuto': false,
'smaller': false,
'pdfSeparateFragments': false,
'autoAnimateEasing': "ease",
'autoAnimateDuration': 1,
'autoAnimateUnmatched': true,
'menu': {"side":"left","useTextContentForMissingTitles":true,"markers":false,"loadIcons":false,"custom":[{"title":"Tools","icon":"<i class=\"fas fa-gear\"></i>","content":"<ul class=\"slide-menu-items\">\n<li class=\"slide-tool-item active\" data-item=\"0\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.fullscreen(event)\"><kbd>f</kbd> Fullscreen</a></li>\n<li class=\"slide-tool-item\" data-item=\"1\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.speakerMode(event)\"><kbd>s</kbd> Speaker View</a></li>\n<li class=\"slide-tool-item\" data-item=\"2\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.overview(event)\"><kbd>o</kbd> Slide Overview</a></li>\n<li class=\"slide-tool-item\" data-item=\"3\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.togglePdfExport(event)\"><kbd>e</kbd> PDF Export Mode</a></li>\n<li class=\"slide-tool-item\" data-item=\"4\"><a href=\"#\" onclick=\"RevealMenuToolHandlers.keyboardHelp(event)\"><kbd>?</kbd> Keyboard Help</a></li>\n</ul>"}],"openButton":true},
'smaller': false,
 
        // Display controls in the bottom right corner
        controls: false,

        // Help the user learn the controls by providing hints, for example by
        // bouncing the down arrow when they first encounter a vertical slide
        controlsTutorial: false,

        // Determines where controls appear, "edges" or "bottom-right"
        controlsLayout: 'edges',

        // Visibility rule for backwards navigation arrows; "faded", "hidden"
        // or "visible"
        controlsBackArrows: 'faded',

        // Display a presentation progress bar
        progress: true,

        // Display the page number of the current slide
        slideNumber: 'c/t',

        // 'all', 'print', or 'speaker'
        showSlideNumber: 'all',

        // Add the current slide number to the URL hash so that reloading the
        // page/copying the URL will return you to the same slide
        hash: true,

        // Start with 1 for the hash rather than 0
        hashOneBasedIndex: false,

        // Flags if we should monitor the hash and change slides accordingly
        respondToHashChanges: true,

        // Push each slide change to the browser history
        history: true,

        // Enable keyboard shortcuts for navigation
        keyboard: true,

        // Enable the slide overview mode
        overview: true,

        // Disables the default reveal.js slide layout (scaling and centering)
        // so that you can use custom CSS layout
        disableLayout: false,

        // Vertical centering of slides
        center: false,

        // Enables touch navigation on devices with touch input
        touch: true,

        // Loop the presentation
        loop: false,

        // Change the presentation direction to be RTL
        rtl: false,

        // see https://revealjs.com/vertical-slides/#navigation-mode
        navigationMode: 'linear',

        // Randomizes the order of slides each time the presentation loads
        shuffle: false,

        // Turns fragments on and off globally
        fragments: true,

        // Flags whether to include the current fragment in the URL,
        // so that reloading brings you to the same fragment position
        fragmentInURL: false,

        // Flags if the presentation is running in an embedded mode,
        // i.e. contained within a limited portion of the screen
        embedded: false,

        // Flags if we should show a help overlay when the questionmark
        // key is pressed
        help: true,

        // Flags if it should be possible to pause the presentation (blackout)
        pause: true,

        // Flags if speaker notes should be visible to all viewers
        showNotes: false,

        // Global override for autoplaying embedded media (null/true/false)
        autoPlayMedia: null,

        // Global override for preloading lazy-loaded iframes (null/true/false)
        preloadIframes: null,

        // Number of milliseconds between automatically proceeding to the
        // next slide, disabled when set to 0, this value can be overwritten
        // by using a data-autoslide attribute on your slides
        autoSlide: 0,

        // Stop auto-sliding after user input
        autoSlideStoppable: true,

        // Use this method for navigation when auto-sliding
        autoSlideMethod: null,

        // Specify the average time in seconds that you think you will spend
        // presenting each slide. This is used to show a pacing timer in the
        // speaker view
        defaultTiming: null,

        // Enable slide navigation via mouse wheel
        mouseWheel: false,

        // The display mode that will be used to show slides
        display: 'block',

        // Hide cursor if inactive
        hideInactiveCursor: true,

        // Time before the cursor is hidden (in ms)
        hideCursorTime: 5000,

        // Opens links in an iframe preview overlay
        previewLinks: false,

        // Transition style (none/fade/slide/convex/concave/zoom)
        transition: 'slide',

        // Transition speed (default/fast/slow)
        transitionSpeed: 'default',

        // Transition style for full page slide backgrounds
        // (none/fade/slide/convex/concave/zoom)
        backgroundTransition: 'none',

        // Number of slides away from the current that are visible
        viewDistance: 3,

        // Number of slides away from the current that are visible on mobile
        // devices. It is advisable to set this to a lower number than
        // viewDistance in order to save resources.
        mobileViewDistance: 2,

        // The "normal" size of the presentation, aspect ratio will be preserved
        // when the presentation is scaled to fit different resolutions. Can be
        // specified using percentage units.
        width: 1050,

        height: 700,

        // Factor of the display size that should remain empty around the content
        margin: 0.1,

        math: {
          mathjax: 'https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js',
          config: 'TeX-AMS_HTML-full',
          tex2jax: {
            inlineMath: [['\\(','\\)']],
            displayMath: [['\\[','\\]']],
            balanceBraces: true,
            processEscapes: false,
            processRefs: true,
            processEnvironments: true,
            preview: 'TeX',
            skipTags: ['script','noscript','style','textarea','pre','code'],
            ignoreClass: 'tex2jax_ignore',
            processClass: 'tex2jax_process'
          },
        },

        // reveal.js plugins
        plugins: [QuartoLineHighlight, PdfExport, RevealMenu, QuartoSupport,

          RevealMath,
          RevealNotes,
          RevealSearch,
          RevealZoom
        ]
      });
    </script>
    <script id="quarto-html-after-body" type="application/javascript">
    window.document.addEventListener("DOMContentLoaded", function (event) {
      const toggleBodyColorMode = (bsSheetEl) => {
        const mode = bsSheetEl.getAttribute("data-mode");
        const bodyEl = window.document.querySelector("body");
        if (mode === "dark") {
          bodyEl.classList.add("quarto-dark");
          bodyEl.classList.remove("quarto-light");
        } else {
          bodyEl.classList.add("quarto-light");
          bodyEl.classList.remove("quarto-dark");
        }
      }
      const toggleBodyColorPrimary = () => {
        const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
        if (bsSheetEl) {
          toggleBodyColorMode(bsSheetEl);
        }
      }
      toggleBodyColorPrimary();  
      const tabsets =  window.document.querySelectorAll(".panel-tabset-tabby")
      tabsets.forEach(function(tabset) {
        const tabby = new Tabby('#' + tabset.id);
      });
      const isCodeAnnotation = (el) => {
        for (const clz of el.classList) {
          if (clz.startsWith('code-annotation-')) {                     
            return true;
          }
        }
        return false;
      }
      const clipboard = new window.ClipboardJS('.code-copy-button', {
        text: function(trigger) {
          const codeEl = trigger.previousElementSibling.cloneNode(true);
          for (const childEl of codeEl.children) {
            if (isCodeAnnotation(childEl)) {
              childEl.remove();
            }
          }
          return codeEl.innerText;
        }
      });
      clipboard.on('success', function(e) {
        // button target
        const button = e.trigger;
        // don't keep focus
        button.blur();
        // flash "checked"
        button.classList.add('code-copy-button-checked');
        var currentTitle = button.getAttribute("title");
        button.setAttribute("title", "Copied!");
        let tooltip;
        if (window.bootstrap) {
          button.setAttribute("data-bs-toggle", "tooltip");
          button.setAttribute("data-bs-placement", "left");
          button.setAttribute("data-bs-title", "Copied!");
          tooltip = new bootstrap.Tooltip(button, 
            { trigger: "manual", 
              customClass: "code-copy-button-tooltip",
              offset: [0, -8]});
          tooltip.show();    
        }
        setTimeout(function() {
          if (tooltip) {
            tooltip.hide();
            button.removeAttribute("data-bs-title");
            button.removeAttribute("data-bs-toggle");
            button.removeAttribute("data-bs-placement");
          }
          button.setAttribute("title", currentTitle);
          button.classList.remove('code-copy-button-checked');
        }, 1000);
        // clear code selection
        e.clearSelection();
      });
      function tippyHover(el, contentFn) {
        const config = {
          allowHTML: true,
          content: contentFn,
          maxWidth: 500,
          delay: 100,
          arrow: false,
          appendTo: function(el) {
              return el.closest('section.slide') || el.parentElement;
          },
          interactive: true,
          interactiveBorder: 10,
          theme: 'light-border',
          placement: 'bottom-start'
        };
          config['offset'] = [0,0];
          config['maxWidth'] = 700;
        window.tippy(el, config); 
      }
      const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
      for (var i=0; i<noterefs.length; i++) {
        const ref = noterefs[i];
        tippyHover(ref, function() {
          // use id or data attribute instead here
          let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
          try { href = new URL(href).hash; } catch {}
          const id = href.replace(/^#\/?/, "");
          const note = window.document.getElementById(id);
          return note.innerHTML;
        });
      }
      const findCites = (el) => {
        const parentEl = el.parentElement;
        if (parentEl) {
          const cites = parentEl.dataset.cites;
          if (cites) {
            return {
              el,
              cites: cites.split(' ')
            };
          } else {
            return findCites(el.parentElement)
          }
        } else {
          return undefined;
        }
      };
      var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
      for (var i=0; i<bibliorefs.length; i++) {
        const ref = bibliorefs[i];
        const citeInfo = findCites(ref);
        if (citeInfo) {
          tippyHover(citeInfo.el, function() {
            var popup = window.document.createElement('div');
            citeInfo.cites.forEach(function(cite) {
              var citeDiv = window.document.createElement('div');
              citeDiv.classList.add('hanging-indent');
              citeDiv.classList.add('csl-entry');
              var biblioDiv = window.document.getElementById('ref-' + cite);
              if (biblioDiv) {
                citeDiv.innerHTML = biblioDiv.innerHTML;
              }
              popup.appendChild(citeDiv);
            });
            return popup.innerHTML;
          });
        }
      }
    });
    </script>
    

</body></html>